IX. 510(k) Summary

SUBMITTER:

DePuy Spine, Inc.

325 Paramount Drive Raynham, MA 02780

CONTACT PERSON:

Lisa A. Gilman

DATE PREPARED:

June 18, 2004

CLASSIFICATION NAME: Implant, Fixation Device

Spinal Intervertebral Body Fixation Orthosis Device

PROPRIETARY NAME:

VBR Spinal System

PREDICATE DEVICES:

DePuy AcroMed VBR System (K030833) DePuy AcroMed VBR System (K031635)

Stackable Cage System (K990148)

Surgical Titanium Mesh System (K020522)

Devex Mesh System (K023835)

DEVICE DESCRIPTION: Additional components in various sizes and footprints.

The VBR Spinal System also contains Class 1 manual surgical instruments and cases that are

considered exempt from premarket notification.

INTENDED USE:

The VBR Spinal System is indicated for use in the thoracolumbar spine (i.e., T1-L5) to replace a diseased vertebral body resected or excised for the achieve anterior treatment of tumors. to decompression of the spinal cord and neural tissues, and to restore the height of a collapsed vertebral

body.

The VBR Spinal System is also indicated for treating

fractures of the thoracic and lumbar spine.

The VBR Spinal System is designed to restore the biomechanical integrity of the anterior, middle and posterior spinal column even in the absence of fusion

for a prolonged period.

The VBR Spinal System is intended for use with supplemental internal fixation. The supplemental internal fixation systems that may be used with the VBR Spinal System include DePuy Spine titanium plate or rod systems (i.e., Kaneda SR, University Plate, M-2, ISOLA, VSP, Moss Miami, TiMX, MONARCH, and Profile).

MATERIALS:

Carbon-fiber reinforced polymer

PERFORMANCE

DATA:

Performance data were submitted to characterize the additional components of the VBR Spinal System.





SEP 2 3 7004

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Lisa Gilman Regulatory Affairs Associate Depuy Spine, Inc. 325 Paramount Drive Raynham, Massachusetts 02767-0350

Re: K041722

Trade/Device Name: VBR Spinal System Regulatory Number: 21 CFR 888.3060

Regulation Name: Spinal intervertebral body fixation orthosis

Regulatory Class: II Product Code: MQP Dated: August 23, 2004 Received: August 24, 2004

Dear Ms. Gilman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4692. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use